Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Cho, Byoung ChulByoung ChulChoAbreu, Delvys RodriguezDelvys RodriguezAbreuHussein, MaenMaenHusseinCobo, ManuelManuelCoboPatel, Anjan JAnjan JPatelSecen, NevenaNevenaSecenLee, Ki HyeongKi HyeongLeeMassuti, BartomeuBartomeuMassutiHiret, SandrineSandrineHiretCHIH-HSIN YANGBarlesi, FabriceFabriceBarlesiLee, Dae HoDae HoLeeAres, Luis PazLuis PazAresHsieh, Robert WRobert WHsiehPatil, Namrata SNamrata SPatilTwomey, PatrickPatrickTwomeyYang, XiaoyingXiaoyingYangMeng, RaymondRaymondMengJohnson, Melissa LMelissa LJohnson2023-03-022023-03-022022-061470-2045https://scholars.lib.ntu.edu.tw/handle/123456789/628834Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for non-small-cell lung cancer (NSCLC).en[SDGs]SDG3Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyjournal article10.1016/S1470-2045(22)00226-1355769572-s2.0-85130688627WOS:000831830800023https://api.elsevier.com/content/abstract/scopus_id/85130688627